Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

4535 - BAYOU: Phase 2 Study of Efficacy and Safety of Durvalumab plus Olaparib as First-line Therapy in Platinum-ineligible Patients (pts) with Stage IV Urothelial Cancer (UC)

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Tumour Site

Urothelial Cancers

Presenters

Jonathan Rosenberg

Citation

Annals of Oncology (2018) 29 (suppl_8): viii303-viii331. 10.1093/annonc/mdy283

Authors

J.E. Rosenberg1, D.F. Bajorin1, A. Smith2, C. D’cruz3, M. Lanasa4

Author affiliations

  • 1 Genitourinary Oncology, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 2 Biometrics & Information Sciences, AstraZeneca, Cambridge/GB
  • 3 Gmed Cancer Immunotherapy, AstraZeneca, Gaithersburg/US
  • 4 Gmed Cancer Immunotherapy, AstraZeneca, 20878 - Gaithersburg/US
More

Resources

Abstract 4535

Background

UC is platinum-responsive and hypothesized to be sensitive to targeted DNA-damaging agents such as PARP inhibitors (PARPi). Cisplatin (cis)-ineligible pts with metastatic/unresectable primary UC have limited effective treatment options. Immune checkpoint blockade may increase the proportion of pts that respond to PARPi. Durvalumab is a selective, high-affinity, engineered, human IgG1 monoclonal Ab that blocks PD-L1 binding to PD-1 and CD80. In UC, the combination of olaparib (a PARPi) + durvalumab may broaden the therapeutic effect of monotherapy given their different mechanisms of action, with potentially enhanced benefit for pts with metastatic/unresectable UC and DNA repair deficiencies (mutations in homologous recombination repair genes [HRRm]).

Trial design

BAYOU is a double-blind, randomized, placebo-controlled, multicenter phase 2 study designed to assess the efficacy and safety of durvalumab + olaparib vs durvalumab + placebo in cis-ineligible pts with stage IV UC. Adult pts (≥18 years) who are cis-ineligible with histologically/cytologically confirmed unresectable stage IV UC, WHO performance status 0-2, and with known HRRm status will be enrolled. Pts with active/prior autoimmune disorders, brain metastases, prior PARPi/immune therapy, current/prior immunosuppressive agents, non-UC invasive malignancies, and concomitant use of strong CYP3A inhibitors/inducers are excluded. All pts will be randomized (1:1) to durvalumab (1500 mg intravenous, every 4 weeks) + placebo or durvalumab + olaparib (tablet) until disease progression. Olaparib dose will be 300 mg twice daily in pts with CrCl >50 mL/min and 200 mg twice daily in pts with CrCl ≥31 to ≤ 50 mL/min. The primary endpoint is progression-free survival in HRRm patients (investigator assessed, RECIST v1.1). Secondary endpoints are overall survival (OS), duration of response, objective response rate, proportion of pts alive and progression free at 6 months, and OS at 18 months. Safety, pharmacokinetics, and immunogenicity will also be assessed. The trial is currently enrolling pts.

Clinical trial identification

Legal entity responsible for the study

AstraZeneca.

Funding

AstraZeneca.

Editorial Acknowledgement

Editorial assistance, which was in accordance with Good Publication Practice (GPP3) guidelines, was provided by Ingrid Monteiro of Cactus Communications (Mumbai, India).

Disclosure

J.E. Rosenberg: Stockholder: Ilumina; Advisory board: Merck, BMS, AstraZeneca, EMD-Serono, Roche/Genentech, Inovio; Corporate-sponsored research: Roche/Genentech, Seattle Genetics, Astellas, Novartis. D.F. Bajorin: Advisory board or board of directors: Merck, Genentech, Bristol-Myers Squibb, Urogen, Novartis; Corporate-sponsored research: Merck, Novartis. A. Smith, C. D’Cruz, M. Lanasa: Employment: AstraZeneca; Stockholder: AstraZeneca.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.